In short
Amniotic membrane, derived from human tissue, is being studied as a potential treatment for patients with advanced corneal ulcers that have not responded to conventional therapies. This innovative approach involves using a nanostructured artificial cornea to address severe corneal diseases for which there are currently limited effective treatments. The clinical trial aims to evaluate the safety, feasibility, and potential clinical efficacy of this groundbreaking technique.
At a glance
- Study Type
- Multicenter clinical trial
- Main Objective
- Evaluate safety, feasibility, and efficacy of human artificial nanostructured lamellar cornea
- Target Condition
- Advanced corneal trophic ulcers refractory to conventional treatment
- Key Inclusion Criteria
- Age ≥18, Stage 3 Mackie corneal ulcers, minimum 6 weeks disease duration
- Key Exclusion Criteria
- Active ocular infection, bullous keratopathy, positive serology for certain diseases
- Primary Endpoints
- Adverse events, graft conditions, infection signs, induced corneal vascularization
- Secondary Endpoints
- Ulcer persistence, corneal transparency, quality of life, corneal surface characterization
- Investigational Product
- Amniotic membrane (human) as living tissue equivalent
What is Amniotic Membrane?
Amniotic membrane, also known as human amniotic membrane, is a unique biological material derived from the innermost layer of the placenta. In medical applications, it is used as a living tissue equivalent, which means it can be transplanted into the human body to support healing and tissue regeneration.
Medical Conditions Treated
Amniotic membrane is being studied as a potential treatment for several eye conditions, particularly advanced corneal ulcers that have not responded to conventional treatments. These conditions include:
- Corneal trophic ulcers: These are persistent defects in the cornea (the clear front part of the eye) that don't heal properly.
- Stromal thinning: A condition where the middle layer of the cornea becomes thinner.
- Corneal fibrosis: The formation of scar tissue on the cornea.
- Limbal insufficiency: A condition where the stem cells at the edge of the cornea are damaged or missing.
These conditions can be associated with various underlying causes, such as genetic disorders, autoimmune diseases, infections, or injuries.
How It Works
Amniotic membrane is used as a biological bandage or scaffold for the eye. When applied to the cornea, it can:
- Promote healing of the corneal surface
- Reduce inflammation
- Prevent scarring
- Support the growth of new, healthy corneal cells
The membrane is typically implanted onto the eye's surface during a surgical procedure.
Clinical Trial Overview
A multicenter clinical trial is being conducted to evaluate the safety and feasibility of using amniotic membrane along with allogeneic stem cells to create a nanostructured artificial human cornea. This innovative approach aims to help patients with severe corneal diseases for which there are currently no effective treatments.
The main objectives of the trial are to:
- Assess the safety of the artificial cornea
- Evaluate how well the graft integrates and survives
- Determine if there's evidence of clinical effectiveness
Eligibility Criteria
To participate in this clinical trial, patients must meet specific criteria, including:
- Age 18 or older
- Having a severe corneal ulcer (Stage 3 Mackie) that hasn't responded to conventional treatments for at least 6 weeks
- No active eye infections
- Normal blood test results
Certain conditions may exclude a person from participating, such as pregnancy, active cancer, or recent participation in other clinical trials.
Potential Benefits
If successful, this treatment could offer hope to patients with severe corneal diseases by:
- Healing persistent corneal ulcers
- Improving corneal transparency
- Regenerating damaged corneal tissue
- Enhancing overall quality of life
Safety Considerations
As with any medical treatment, there are potential risks and safety considerations. The clinical trial will closely monitor for:
- Adverse events related to the treatment
- Signs of infection (local, regional, or systemic)
- Graft rejection or failure
- Induced corneal vascularization (growth of blood vessels into the cornea)
It's important to note that this treatment is still in the research phase, and its long-term safety and effectiveness are being evaluated.